CCM
AEGR

Consonance Capital Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Consonance Capital Management’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-758,970
Closed -$35M – 31
2014
Q1 		$35M Buy
758,970
+221,936
+41% +$13M 5.21% 6
2013
Q4 		$38.1M Buy
+537,034
New +$41.1M 6.25% 4

Other funds holding AEGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Consonance Capital Management's AEGR Position: Q2 2014 in Review

Consonance Capital Management sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2014, closing a stake of 758,970 shares — an estimated $35M sold.

Consonance Capital Management first reported a position in AEGR in Q4 2013 and held it in 2 quarters. The position peaked at $38.1M in Q4 2013. 129 funds tracked by Wall St. Rank hold AEGR as of Q2 2014.

  • Consonance Capital Management reported no remaining Aegerion Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Consonance Capital Management sold 758,970 Aegerion Pharmaceuticals shares in Q2 2014, an estimated $35M.
  • Consonance Capital Management first reported a position in Aegerion Pharmaceuticals in Q4 2013 and held it in 2 quarters.
  • Consonance Capital Management's Aegerion Pharmaceuticals position peaked at $38.1M in Q4 2013.
  • 129 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2014.

Based on Consonance Capital Management's 13F filing for Q2 2014, filed 12 Aug 2014.